Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Research and Markets: Atopic Dermatitis (Eczema) - Pipeline Review, H2 2012

Research and Markets
Posted on: 11 Oct 12

Research and Markets ( has announced the addition of Global Markets Direct's new report "Atopic Dermatitis (Eczema) - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Atopic Dermatitis (Eczema) - Pipeline Review, H2 2012', provides an overview of the Atopic Dermatitis (Eczema) therapeutic pipeline. This report provides information on the therapeutic development for Atopic Dermatitis (Eczema), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atopic Dermatitis (Eczema).

'Atopic Dermatitis (Eczema) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


- A snapshot of the global therapeutic scenario for Atopic Dermatitis (Eczema).

- A review of the Atopic Dermatitis (Eczema) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Atopic Dermatitis (Eczema) pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- News and deals relating to the products.

Reasons to Buy:

- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis (Eczema).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis (Eczema) pipeline depth and focus of Atopic Dermatitis (Eczema) therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit

Source: Global Markets Direct

Business Wire

Last updated on: 11/10/2012

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.